Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing
MIKE DERER/AP
Want to know why an industry that views itself as lifesaving and heroic is viewed by much of the public as price gouging and venal? Look here.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario